APA (7th ed.) Citation

Kurino, T., Matsuda, R., Terui, A., Suzuki, H., Kokubo, T., Uehara, T., . . . Hatakeyama, H. Poor outcome with anti-programmed death-ligand 1 (PD-L1) antibody due to poor pharmacokinetic properties in PD-1/PD-L1 blockade-sensitive mouse models. BMJ Publishing Group.

Chicago Style (17th ed.) Citation

Kurino, Taiki, Reiko Matsuda, Ayu Terui, Hiroyuki Suzuki, Tomomi Kokubo, Tomoya Uehara, Yasushi Arano, Akihiro Hisaka, and Hiroto Hatakeyama. Poor Outcome with Anti-programmed Death-ligand 1 (PD-L1) Antibody Due to Poor Pharmacokinetic Properties in PD-1/PD-L1 Blockade-sensitive Mouse Models. BMJ Publishing Group.

MLA (9th ed.) Citation

Kurino, Taiki, et al. Poor Outcome with Anti-programmed Death-ligand 1 (PD-L1) Antibody Due to Poor Pharmacokinetic Properties in PD-1/PD-L1 Blockade-sensitive Mouse Models. BMJ Publishing Group.